Kodiak Sciences (NASDAQ:KOD) Given "Neutral" Rating at HC Wainwright

HC Wainwright reissued their neutral rating on shares of Kodiak Sciences (NASDAQ:KOD - Free Report) in a report published on Monday morning,Benzinga reports. HC Wainwright currently has a $3.00 price objective on the stock. HC Wainwright also issued estimates for Kodiak Sciences' Q1 2025 earnings at ($0.90) EPS, Q2 2025 earnings at ($0.99) EPS, Q3 2025 earnings at ($1.10) EPS, Q4 2025 earnings at ($1.23) EPS, FY2025 earnings at ($4.23) EPS, FY2026 earnings at ($4.63) EPS, FY2027 earnings at ($4.10) EPS, FY2028 earnings at ($2.90) EPS and FY2029 earnings at ($1.51) EPS.

Separately, Jefferies Financial Group upgraded Kodiak Sciences from a "hold" rating to a "buy" rating and set a $20.00 target price on the stock in a research report on Monday, December 9th.

Kodiak Sciences Stock Down 10.2 %

Shares of KOD traded down $0.25 on Monday, hitting $2.16. 229,842 shares of the stock traded hands, compared to its average volume of 344,113. The firm has a market capitalization of $113.67 million, a P/E ratio of -0.59 and a beta of 2.40. The stock's 50 day moving average is $4.44 and its two-hundred day moving average is $5.41. Kodiak Sciences has a 1 year low of $2.11 and a 1 year high of $11.60.

Kodiak Sciences (NASDAQ:KOD - Get Free Report) last released its quarterly earnings data on Thursday, March 27th. The company reported ($0.84) EPS for the quarter, beating the consensus estimate of ($0.90) by $0.06. Research analysts forecast that Kodiak Sciences will post -3.45 EPS for the current year.

Remove Ads

Hedge Funds Weigh In On Kodiak Sciences

Several institutional investors and hedge funds have recently modified their holdings of the stock. Public Employees Retirement System of Ohio grew its stake in Kodiak Sciences by 183.9% in the fourth quarter. Public Employees Retirement System of Ohio now owns 14,759 shares of the company's stock valued at $147,000 after purchasing an additional 9,560 shares in the last quarter. Two Sigma Investments LP increased its stake in shares of Kodiak Sciences by 25.2% during the 4th quarter. Two Sigma Investments LP now owns 49,406 shares of the company's stock worth $492,000 after purchasing an additional 9,941 shares during the last quarter. Point72 Asset Management L.P. acquired a new stake in shares of Kodiak Sciences in the fourth quarter worth $5,211,000. Millennium Management LLC boosted its position in shares of Kodiak Sciences by 148.7% in the fourth quarter. Millennium Management LLC now owns 81,991 shares of the company's stock valued at $816,000 after acquiring an additional 49,019 shares during the period. Finally, Deutsche Bank AG increased its holdings in shares of Kodiak Sciences by 16.2% during the 4th quarter. Deutsche Bank AG now owns 67,546 shares of the company's stock worth $672,000 after purchasing an additional 9,433 shares during the period. 89.06% of the stock is currently owned by hedge funds and other institutional investors.

Kodiak Sciences Company Profile

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.